| [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. | |
| | |
MedLine Citation:
|
PMID: 17414758 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: We retrospectively assessed the diagnostic utility of dedicated positron emission tomography (PET) and hybrid PET-computed tomography (CT) scans with [F-18]fluorodeoxyglucose (FDG) in the imaging evaluation of patients with known or suspected recurrent and metastatic cholangiocarcinoma. METHODS: The study group included 24 patients (13 males and 11 females; age range, 34-75 years) with known or suspected recurrent and metastatic cholangiocarcinoma. We performed 8 dedicated PET scans (Siemens 953/A, Knoxville, Tenn) in 8 patients and 24 hybrid PET-CT scans (Siemens Biograph, Knoxville, Tenn) in 16 patients. Four patients underwent both pretreatment and posttreatment scans. Nonenhanced CT transmission scans were obtained for attenuation correction after administration of oral contrast material. PET images were obtained 60 minutes after the intravenous administration of 15 mCi (555 MBq) FDG. Prior treatments included surgery alone in 12 patients, surgery and chemotherapy in 6 patients, and surgery and combined chemoradiation therapy in 6 patients. Diagnostic validation was conducted through clinical and radiologic follow-up (2 months to 8 years). RESULTS: PET and CT were concordant in 18 patients. PET-CT correctly localized a hypermetabolic metastatic lesion in the anterior subdiaphragmatic fat instead of within the liver and was falsely negative in intrahepatic infiltrating type cholangiocarcinoma. PET was discordant with CT in 6 patients. PET was negative in an enlarged right cardiophrenic lymph node on CT, which remained stable for 1 year. In 1 patient, PET-CT scan showed hypermetabolic peritoneal disease in the right paracolic gutter without definite corresponding structural abnormalities, which was subsequently confirmed on a follow-up PET-CT scan performed 6 months after the initial study, at which time peritoneal nodular thickening was evident on concurrent CT. PET-CT documented the progression of locally recurrent and metastatic disease in another patient based on interval appearance of several new hypermetabolic lesions and significant increase in the standardized uptake values of the known lesions despite little interval change in the size and morphologic character of lesions on concurrent CT. It was also helpful in excluding metabolically active disease in patients with contrast enhancement at either surgical margin of hepatic resection site or focally within hepatic parenchyma and in an osseous lesion. Overall, based on the clinically relevant patient basis for detection of recurrent and metastatic cholangiocarcinoma, the sensitivity and specificity of PET (alone and combined with CT) were 94% and 100% and, for CT alone, were 82% and 43%, respectively. CONCLUSIONS: FDG PET and PET-CT are useful in the imaging evaluation of patients with cholangiocarcinoma (except for infiltrating type) for detection of recurrent and metastatic disease and for assessment of treatment response. In particular, the combined structural and metabolic information of PET-CT enhances the diagnostic confidence in lesion characterization. |
| | |
Authors:
|
Hossein Jadvar; Robert W Henderson; Peter S Conti |
Related Documents
:
|
11995458 - Tumor marker cea in monitoring of response to tegafur-uracil and folinic acid in patien... 2590038 - Modern diagnostic strategy for acoustic neuromas. 10768568 - Pet: the merging of biology and imaging into molecular imaging. 12167578 - Positron emission tomography is superior to computed tomography for metastatic detectio... 2598558 - Orbital pseudotumor imaged with ga-67 citrate. 21798708 - Endoscopically directed middle meatal cultures vs computed tomographic scans in the dia... |
Publication Detail:
|
Type: Evaluation Studies; Journal Article |
Journal Detail:
|
Title: Journal of computer assisted tomography Volume: 31 ISSN: 0363-8715 ISO Abbreviation: J Comput Assist Tomogr Publication Date: 2007 Mar-Apr |
Date Detail:
|
Created Date: 2007-04-06 Completed Date: 2007-05-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7703942 Medline TA: J Comput Assist Tomogr Country: United States |
Other Details:
|
Languages: eng Pagination: 223-8 Citation Subset: IM |
Affiliation:
|
PET Imaging Science Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. jadvar@usc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Bile Duct Neoplasms / diagnosis*, pathology, secondary Bile Ducts, Intrahepatic / radiography, radionuclide imaging Cholangiocarcinoma / diagnosis*, pathology, secondary Female Fluorodeoxyglucose F18 / diagnostic use* Follow-Up Studies Humans Image Enhancement / methods Male Middle Aged Neoplasm Metastasis / diagnosis Neoplasm Recurrence, Local / diagnosis* Neoplasm, Residual Positron-Emission Tomography / methods* Predictive Value of Tests Radiopharmaceuticals / diagnostic use Reproducibility of Results Retrospective Studies Sensitivity and Specificity Tomography, X-Ray Computed / methods* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of 2 different protocols for ingestion of low-attenuating oral contrast agent for multide...
Next Document: Magnetic resonance imaging of endometrial cancer and clear cell cancer.